The FOxTROT trial has closed to recruitment (completed December 2016) and patient follow-up is also nearly complete. 

Further Informatin is avaible from:

FOxTROT Study Office
Email: [email protected]
Ladan Adie (Trial Coordinator) Tel: 0121 414 9013  Email: [email protected]
Georgia Kennedy (Data Manager) Tel: 0121 414 9013 Email: [email protected]
Laura Magill (Colorectal Trials Team Leader) Tel: 0121 415 9105 Email: [email protected]

FOxTROT is a multi-centre randomised controlled trial (RCT) of Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for high risk colon cancer .

This trial was developed by the NCRI Colorectal Cancer Study Group and is funded by Cancer Research UK.

Primary objectives:

  • To determine if neoadjuvant chemotherapy±panitumumab followed by deferred surgery and completion of chemotherapy post-operatively can reduce 2-year recurrence as compared to surgery and postoperative chemotherapy±panitumumab
  • To determine if adding panitumumab in the neoadjuvant treatment produces a measurable increase in anti-tumour efficacy as measured by tumour shrinkage.


The trial aimed to recruit 1050 patients over 4 years.

© Copyright 2021 BSGAR